Summary by Moomoo AI
BlackRock, Inc., a global investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on October 22, 2024, indicating a 7.5% ownership stake in Recursion Pharmaceuticals, Inc. This filing, which is an update to previous disclosures, shows that BlackRock now beneficially owns 20,742,797 shares of Class A Common Stock in Recursion Pharmaceuticals. The filing was made under Rule 13d-1(b), which is typically used by passive investors not seeking to change or influence the control of the company. Recursion Pharmaceuticals, headquartered in Salt Lake City, Utah, is the issuer of the securities in question. The filing also includes a list of subsidiaries under BlackRock, Inc. that own 5% or greater of the outstanding shares of the security class being reported.
